Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

30.90 +0.87 (+2.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,242,795
Open	30.26
Bid (Size)	27.50 (500)
Ask (Size)	31.20 (500)
Prev. Close	30.03
Today's Range	29.95 - 31.85
52wk Range	14.40 - 31.99
Shares Outstanding	66,344,236
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Performance

YTD	+14.4%	+14.4%
1 Month	+31.3%	+31.3%
3 Month	+13.3%	+13.3%
6 Month	+24.3%	+24.3%
1 Year	+57.3%	+57.3%

More News

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

Via The Motley Fool

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

March 01, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at

February 27, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗

February 25, 2026

Via Stocktwits

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

February 25, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

February 25, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile

February 23, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Upcoming Investor Conferences

February 09, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics SVPs Engage In Heavy Transactions ↗

January 12, 2026

Via The Motley Fool

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

December 09, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗

November 10, 2025

Via Benzinga

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

November 10, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Upcoming Investor Conferences

November 07, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

November 06, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients

November 06, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

October 30, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Analyst Expectations For Celldex Therapeutics's Future ↗

October 13, 2025

Via Benzinga

Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗

October 03, 2025

Via Chartmill

5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗

September 17, 2025

Via Benzinga

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

September 17, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

September 09, 2025

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?

Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?

Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?

The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market

What is the current price of Celldex Therapeutics, Inc. - Common Stock?

The current price of Celldex Therapeutics, Inc. - Common Stock is 30.90

When was Celldex Therapeutics, Inc. - Common Stock last traded?

The last trade of Celldex Therapeutics, Inc. - Common Stock was at 03/20/26 04:00 PM ET

What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?

The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 2.05B

How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?

Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.